Merck is reattempting reimbursement listing of its MET-targeted anticancer therapy ‘Tepmetko (tepotinib)’ in Korea.

The drug was unable to pass the Health Insurance Review and Assessment Service’s Cancer Disease Deliberation Committee review in February. The company voluntarily withdrew its reimbursement process at the time.

The company had later reorganized the data to reapply for reimbursement.

According to the industry on the 6th, Merck Korea recently applied to request a reimbursement decision for its Tepmetko to HIRA.

Tepmetko is a treatment for locally advanced or metastatic non-small cell lung cancer with confirmed MET exon 14 skipping muta